Regulatory News

DeepMatter Appoints Industry Advisors

16 December 2019

DeepMatter strengthens its depth of knowledge and industry links in Research & Medicinal Chemistry, Process Chemistry and Automation

16 December 2019 - DeepMatter (AIM: DMTR), the AIM-quoted company focusing on digitising chemistry, is delighted to welcome three leading sector figures as industry advisors on its commercial roll-out of DigitalGlassware™. The advisors bring in-depth knowledge in research & medicinal chemistry, process chemistry and industrially focused closed-loop robotics and automation, all target industries for DigitalGlassware™, the Company's innovative cloud-based digital chemistry platform that brings recordability, reproducibility and shareability to the lab.

The advisors will contribute to the ongoing development of the DigitalGlassware™ strategic roadmap and are as follows:

  • Dr Richard Bourne - a leading academic in Process Chemistry. Richard is Associate Professor at the University of Leeds based at the Institute of Process Research and Development, working on rapid process development and continuous flow chemistry. In November 2019, he was announced as a new Royal Academy of Engineering Senior Research Fellow in Digital Manufacturing and Discovery of Pharmaceuticals.
  • Dr John Harris - a pharmaceutical industry consultant with a wealth of research chemistry knowledge and expertise. John was previously Head of the Wellcome Foundation's UK cardiovascular therapeutic area and founder of BioFocus, a highly successful early-stage CRO, now part of the Charles River organisation.
  • Dr David M Parry - an experienced synthetic chemist, with a track record of delivering complex projects within the pharma and biotech sectors. David built and ran a business focused on automated medicinal chemistry, where compounds would be synthesised, then tested in a primary assay on the same platforms, with the results fed back into the software to inform the next round of automated synthesis.

Mark Warne, Chief Executive Officer of DeepMatter, commented:

"We believe DigitalGlassware™ has the opportunity to sit at the heart of the digitisation of chemistry, enabling chemists to produce better molecules, faster and ultimately cheaper. We are delighted to welcome Richard, John and David to the DigitalGlassware™ team, each bringing valuable insight from their three areas of specialism. Their expertise will help ensure the platform meets and integrates the needs of these key disciplines, assisting us in the commercial roll-out of our innovative cloud-based digital chemistry platform."

 

For more information, please contact:

DeepMatter Group plc Tel: +44 (0)141 548 8156
Mark Warne, Chief Executive Officer
Shore Capital(Nominated Adviser and Broker) T: 020 7601 6100
Tom Griffiths
David Coaten
Alma PR
Caroline Forde
Jessica Joynson
Kieran Breheny
+44 (0) 3405 0205
[email protected]

 

About DeepMatter:

DeepMatter's long term strategy is to integrate chemistry with technology, thereby enabling a greater use of artificial intelligence and reaching a point where chemicals can be autonomously synthesised through robotics. In the near term this involves the provision of an integrated software, hardware and artificial intelligence enabled platform, DigitalGlassware™, to scientists across research and process development sectors.

The DigitalGlassware™ platform allows chemistry experiments to be accurately and systematically recorded, coded and entered into a shared data cloud. The platform is designed to enable chemists to work together effectively; sharing the details of their experiments from anywhere and in real-time, so that work is not needlessly duplicated, time and money wasted, and ultimately so new discoveries may be made faster.

Visit: www.deepmatter.io and follow @deepmattergroup